Completely blocking PCSK9 may lead to increased all-cause mortality and does not appear to benefit cardiovascular health long-term. — Whalespan
Completely blocking PCSK9 may lead to increased all-cause mortality and does not appear to benefit cardiovascular health long-term.
⚠ High risk
We can't find evidence that holds up here. Proponents are reasoning from mechanism or analogy rather than direct human data, and the most credible skeptics raise objections we can't dismiss.
✕NOTSUPPORTED
⚠
High-risk intervention — consult a physician before acting.Drug-drug interactions, dose-dependence, and screening contraindications apply.
“our meta-analysis of clinical events registered on clinicaltrials.gov did not show that pcsk9 inhibitors improve cardiovascular health evolocumab it's their monoclonal antibodies increased the risk of all-cause mortality and there are tons of other problems with these things they have all kinds of other side effects they're increasing the risk of all cause mortality”
Conflict Watch
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.